Todd Young
In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a full year. These results sent shock waves through the pharmaceutical industry: the previous best-in-class drug, produced by the U.S. pharmaceutical giant Merck, delayed new tumor growth for only six months.
No comments:
Post a Comment